@article{b44b1701c38f4ebba8857d83f07e26e1,
title = "Pulmonary vasodilator treatment in pulmonary hypertension due to left heart or lung disease: time for a high-definition picture?",
author = "Lucilla Piccari and Bernardo, {Roberto J.} and Diego Rodr{\'i}guez-Chiarad{\'i}a and Patrizio Vitulo and Wort, {S. John} and Sandeep Sahay",
note = "Funding Information: S.S.: Consultancy fees from Janssen Pharmaceutical Companies of Johnson & Johnson, United Therapeutics, Bayer Pharmaceuticals; research/grant support from Chest Foundation (ILD research grant); Scientific medical advisor fees for United Therapeutics, Altavant Sciences, and Liquidia; and Speaker{\textquoteright}s bureau fees from Janssen Pharmaceutical Companies of Johnson & Johnson, Bayer, and United Therapeutics. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
month = may,
day = "12",
doi = "10.1177/20458940211018074",
language = "English (US)",
volume = "11",
journal = "Pulmonary Circulation",
issn = "2045-8932",
publisher = "SAGE Publications Inc.",
number = "2",
}